|
Patent landscape, scope, and claims summary: |
United States Patent 10,004,686: Critical Claim Dissection and US Patent Landscape for Biotin-Targeted Bipolar Lipid Membrane Insulin Delivery
What does US 10,004,686 claim, in operational terms?
US Patent 10,004,686 claims a tightly specified lipid nanoparticle system and multiple downstream uses. The core claim architecture repeats a single technical theme across product, method of manufacturing, and treatment: a bipolar lipid membrane particle (submicron) containing insulin associated noncovalently with the particle, with a single outward-extending biotin ligand that binds biotin-binding hepatocyte receptors.
Independent claim theme (claim 1)
Claim 1 defines a composition with these hard constraints:
-
Particle geometry/materials
- Lipid-based particle defined by a bipolar lipid membrane.
- Membrane lipids include:
- cholesterol
- dicetyl phosphate
- an amphipathic lipid selected from a enumerated group of phospholipids (mostly DSPE/DSPC/DSPG variants and related phosphoethanolamine/phosphocholine/phosphate species; includes racemic glycerol phosphocholine variants).
-
Single hepatocyte targeting ligand
- A hepatocyte receptor binding molecule.
- The composition has “the hepatocyte receptor binding molecule is the only hepatocyte receptor binder in the composition.”
- The hepatocyte binder is a biotin-containing compound selected from:
- biotin DHPE (2,3-diacetoxypropyl 2-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl phosphate)
- biotin-X-DHPE (2,3-diacetoxypropyl 2-(6-(5-((3aS,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)hexanamido) ethyl phosphate)
- any combinations
- The biotin compound extends outward from the particle and binds a biotin-binding hepatocyte receptor.
-
Particle size
- Particle size is specified as 0.0200 to 0.40 μm.
Example dependent layers (claims 2, 4-8)
- Claim 2 adds optional cationic/charged organic molecules (e.g., protamines, polylysine, arginine-containing polymers, histones, amino-containing sugar polymers, amino-group polynucleotides, sulfhydryl proteins, acidic polymers).
- Claims 3 and 4 are manufacturing method variants.
- Claim 4 introduces the internal payload state:
- insulin dispersed within the particle and not covalently bound
- and a free dissolved insulin not dispersed within the particle.
- Claims 5-7 provide:
- separation of free insulin from the particle, and
- optional additive cellulose acetate phthalate.
- Claim 6 narrows separation options to filtration/centrifugation/filter-centrifugation and ion exchange or biotin affinity formats using streptavidin agarose affinity-resin gel and iminobiotin.
Therapeutic framing (claims 9-19)
- Claim 9 uses the same particle spec to treat diabetes with both:
- insulin dispersed in the particle (noncovalent)
- and free dissolved insulin.
- Claim 10 enumerates insulin types (including lispro, aspart, regular, glargine, zinc forms, isophane formulations, etc.).
- Claims 11-12 fix routes, including oral and subcutaneous as explicitly claimed options.
- Claims 14-16 and 18-19 add “increase delivery to hepatocytes” and additional insulin-combination specifics (including glargine and mixed non-glargine set selections; recombinant human insulin isophane combinations).
Kit claims (claims 20-24)
- Claim 20 adds a kit structure: composition + physiological buffer solution + applicator + instructional material.
- Claim 21-23 add kit insulin in contact with composition, including independence of the dispersed and free insulin selection.
- Claim 24 repeats route options including oral/parenteral/subcutaneous/pulmonary/buccal.
Claim map (what is “the invention” vs. what is “a limitation”)
| Element |
Where it appears |
Nature |
Legal impact |
| Bipolar lipid membrane |
claim 1, 3, 4, 9, 14, 18-20 |
core composition definition |
central claim boundary; easy to distinguish from non-bipolar vesicle systems |
| Lipids: cholesterol + dicetyl phosphate + amphipathic phospholipid set |
claim 1 |
hard chemical limitation |
narrows infringement entry points to this membrane recipe |
| Biotin hepatocyte binder, outward extending |
claim 1 |
hard biological targeting limitation |
“only hepatocyte receptor binder” blocks embodiments with extra ligands |
| Biotin DHPE or biotin-X-DHPE |
claim 1 |
hard ligand identity limitation |
narrows to specific conjugates rather than generic biotin derivatives |
| Particle size 0.0200-0.40 μm |
claim 1 |
hard numeric limitation |
supports design-around with size outside range |
| Insulin: dispersed noncovalent + free dissolved |
claim 4 and downstream |
payload state limitation |
creates product-state boundary; separation step matters for methods |
| Charged organic molecule add-on |
claim 2 and related |
optional dependent limitation |
contributes to formulation freedom while keeping core constraints intact |
| Separation using biotin-affinity resins |
claim 6 |
process limitation |
relevant for manufacturing claims and for process-based exclusivity |
| Oral/subcutaneous routes |
claims 11-12, 24 |
route-of-administration limitation |
narrows therapeutic method scope |
Where is the patent likely to be vulnerable: novelty hinges and obviousness pressure points
The claims are specific, but specificity cuts both ways. The landscape risk is highest where the claim contains known materials and known functional pairings, and the patent relies on stitching those elements into one formulation with asserted performance tied to biotin and hepatocyte targeting.
1) “Bipolar lipid membrane” and particle size are likely the main novelty handles
Most independent claim limitations are familiar building blocks in drug delivery: cholesterol, phospholipids, and cationic or charged excipients. The differentiators that may carry the novelty weight are:
- bipolar lipid membrane definition (not just “liposome” or “vesicle”)
- 0.0200 to 0.40 μm particle size window
- use of biotin DHPE / biotin-X-DHPE as the only hepatocyte receptor binder, extending outward
If earlier patents already teach hepatocyte targeting via biotin conjugates on lipid particles, then the “bipolar lipid membrane + exact lipid recipe + exact conjugate identities + size window” become the primary defense.
2) “Only hepatocyte receptor binder” invites design-around
This language is a strict exclusion:
- If a competitor includes another targeting moiety (even another hepatocyte ligand) alongside biotin, the doctrine of equivalents fight becomes harder because the claim explicitly limits the binder set.
Design-around lever:
- Dual-ligand targeting (biotin plus an additional ligand) can aim to fall outside claim literal scope.
3) Insulin “dispersed but not covalently bound” plus “free dissolved insulin” is a tight product-state clause
The manufacturing and treatment claims do not simply claim “an insulin-loaded particle.” They claim a mixture state with two populations:
- insulin dispersed in the particle but not covalently bound
- and free dissolved insulin not dispersed within the particle
That can be difficult to replicate exactly and can be used as a competitor’s partitioning control:
- A competitor formulation strategy that yields only particle-associated insulin (no free insulin), or only free insulin, can be positioned to reduce literal infringement likelihood.
4) Affinity purification language can create process-specific exclusivity
Claim 6 includes:
- streptavidin agarose affinity-resin gel affinity for biotin
- iminobiotin
If the manufacturing process in practice differs (e.g., tangential flow filtration, ultracentrifugation without affinity steps), process claim coverage narrows. Still, the product claims remain.
How the claim set aligns with the insulin delivery pipeline
The claims span:
- composition (claim 1),
- manufacturing methods (claims 3-8),
- treatment methods (claims 9, 14, 18),
- routes (claims 11-12, 24),
- kits (claims 20-24).
This breadth makes the patent relevant to multiple commercialization paths, but enforceability often depends on whether the commercial formulation matches:
- the bipolar lipid membrane recipe,
- the specific biotin conjugates,
- the particle size range,
- and the insulin partitioning state.
What is the US patent landscape likely to look like around this technology?
Given the constrained claim elements, the most relevant prior art and adjacent IP typically clusters around:
- Biotin-functionalized lipid particles/vesicles for receptor-mediated uptake.
- Hepatocyte receptor binding via biotin/biotin-binding receptor systems.
- Insulin delivery using lipid nanoparticles and particle size-defined vesicles.
- Insulin formulation technologies that manage free vs encapsulated insulin fractions.
- Use of cationic polymers/protamine/histones to stabilize insulin or complexes for delivery.
However, without the actual bibliographic and prosecution history details for US 10,004,686 (publication number, filing date, and full spec), the landscape cannot be mapped with precision to specific earlier US references, since search results depend on:
- priority date windows,
- inventor/assignee,
- counterpart filings (WO/EP),
- and the exact “bipolar lipid membrane” definition used in the specification.
Per the constraints, no incomplete or speculative “citation” can be produced.
Critical reading of the claim language: leverage points for investors and R&D
Even without external references, the claim language itself indicates where competitors will test patent boundaries.
A. Substitute ligands or ligand presentation
- Claim demands the hepatocyte binder is only the biotin-containing compound and is one of two specific conjugates (biotin DHPE or biotin-X-DHPE).
- Replacing the conjugate with:
- free biotin,
- biotin-PEG-lipid,
- biotin on a different scaffold,
- or biotin via different linker chemistry,
creates a literal gap if the claim requires these exact conjugates.
B. Particle size engineering
- 0.0200-0.40 μm sets a narrow design window.
- Size-shifting formulation (e.g., producing mostly 10-50 nm or mostly 0.5-1.0 μm) aims to exit the claim.
C. Insulin partitioning control
If a commercial product targets:
- complete encapsulation with no free insulin fraction,
or
- a formulation where insulin is covalently attached,
then the “dispersed noncovalently plus free dissolved insulin” conditions can be targeted.
D. Inclusion of additional binders
The “only hepatocyte receptor binder” constraint is likely to be a litigation lever:
- a competitor can include another hepatocyte-binding ligand while keeping biotin to claim non-infringement on literal binder exclusivity.
E. Manufacturing divergence
Manufacturing claims matter if:
- competitors use a similar contact-and-form mechanism with the same insulin state and then use the same separation approach.
- Process steps like biotin-affinity separation can be avoided to reduce process claim exposure.
Risk summary for freedom-to-operate (FTO) decisions
The claims are narrow on chemistry and ligand identity but broad on therapeutic use and insulin type selection. The FTO risk concentrates on:
- exact lipid recipe (cholesterol + dicetyl phosphate + enumerated amphipathic phospholipid set),
- exact biotin conjugates and their outward extension,
- particle size 0.0200-0.40 μm,
- insulin state with both dispersed noncovalent insulin and free dissolved insulin,
- and exclusivity of the hepatocyte binder.
If commercial candidates deviate materially on any of these, infringement risk falls.
Key Takeaways
- US 10,004,686 claims a bipolar lipid membrane particle with a fixed membrane composition (cholesterol + dicetyl phosphate + enumerated amphipathic phospholipids) and a single outward-extending hepatocyte biotin binder limited to biotin DHPE or biotin-X-DHPE.
- The patent’s enforcement leverage depends on strict technical matches: particle size (0.0200-0.40 μm), binder exclusivity, and insulin partitioning (dispersed noncovalently plus free dissolved insulin).
- The strongest design-around vectors are: size outside range, different biotin scaffold, adding additional hepatocyte binders, and eliminating the free dissolved insulin fraction or changing insulin covalent state.
- The manufacturing and separation claims add process-specific boundaries, particularly where biotin affinity resins are used.
FAQs
-
Is “biotin” alone enough to fall within the claims?
No. The claim limits the hepatocyte receptor binder to biotin DHPE or biotin-X-DHPE (or combinations), and requires it to be the only hepatocyte receptor binder in the composition.
-
Do the claims cover insulin that is fully encapsulated?
The independent method claim 4 and downstream treatment claim set requires both: insulin dispersed within the particle not covalently bound, and free dissolved insulin not dispersed within the particle.
-
What particle sizes are explicitly protected?
The claims require 0.0200 to 0.40 μm for the lipid-based particle.
-
Can a competitor add another targeting ligand alongside biotin?
Claim 1 requires the biotin compound is the only hepatocyte receptor binder. Adding additional hepatocyte-binding ligands targets a literal avoidance argument.
-
Are oral routes covered?
Yes. The therapeutic method claims include administration routes including oral (claim 11) and the kit route claim includes oral (claim 24).
References (APA)
[1] United States Patent 10,004,686 (claims provided in prompt).
More… ↓
⤷ Start Trial
|
